Diary - News All news ENYO Pharma SA announces successful completion of EYP001 first in man Phase 1 study

ENYO Pharma SA announces successful completion of EYP001 first in man Phase 1 study

Study results confirm that FXR agonist EYP001 is safe and well tolerated in healthy subjects and demonstrates engagement of nuclear receptor FXR related biology.

EYP001 is advancing according to the initial plan for chronic hepatitis B and is also exploring expansion for use in other liver indications, such as NASH.

Lyon, June 14, 2017 - ENYO Pharma SA, a privately held biopharmaceutical company currently focused on developing treatments for viral infections, today announced that the Phase 1a single and multiple ascending dose trial evaluating EYP001 in healthy subjects has been completed. The results show that EYP001 was safe and well-tolerated at all doses studied in 80 subjects.